Advinus is responsible for discovery and development work until Phase IIa trials.

Advinus Therapeutics and Ortho-McNeil-Janssen Pharmaceuticals (OMJPI) are working together to discover and develop drugs for various disease targets. Advinus stands to earn up to $247 million, which includes an upfront payment and milestone fees related to development of two targets.

Advinus will be responsible for discovery and development until the completion of Phase IIa studies. OMPJI will have an option to advance the drug candidates into late-stage clinical trials. If the company exercises this option, it will be responsible for worldwide commercialization.

Advinus is also eligible for royalties on the sales of any drug products resulting from the collaboration.

Previous article454’s Sequencer and GenomeQuest’s Informatics Tools to Be Offered Together
Next articleNIH Initiates Five-Year Epigenomics Program with $190M